Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

AstraZeneca U.S. succession plan

  • News

Executive Summary

AstraZeneca Senior VP-U.S. Commercial Operations Tony Zook will replace U.S. President and Exec VP-North America David Brennan effective Jan. 1. Brennan has been named to succeed retiring CEO Tom McKillop (1"The Pink Sheet" Aug. 1, 2005, p. 11). Zook, who joined predecessor company Astra in 1997, previously served as AstraZeneca VP-sales; he has been leading U.S. commercial operations since Brennan was promoted to North America head in 2001 (2"The Pink Sheet" June 4, 2001, p. 32)...
Table

View full table

Advertisement

Related Content

Pink Sheet
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
Pink Sheet
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
Pink Sheet
AstraZeneca

Topics

Advertisement
Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS046321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By